Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
Open Access
- 16 July 2009
- journal article
- letter
- Published by Springer Nature in Diabetologia
- Vol. 52 (9) , 1971-1973
- https://doi.org/10.1007/s00125-009-1452-2
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia, 2009
- Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in SwedenDiabetologia, 2009
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label studyDiabetologia, 2009